Cardinal Health (CAH +1.6%) puts up a decent FQ2 report this morning, despite weaker revenue out...


Cardinal Health (CAH +1.6%) puts up a decent FQ2 report this morning, despite weaker revenue out of its pharmaceutical unit, due in part to brand-to-generic conversions and the loss of the Express Scripts business. Net earnings still managed to rise by 16% Y/Y however, as the drug wholesaler posted better margins. Revenue in its pharmaceutical business its largest by revenue, declined 8%, while its medical business increased by 3%, boosted by last year's acquisition of FutureMed and an additional sales day.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs